TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02143466
Drug: Part A - AZD9291 in combination with MEDI4736
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
Study: NCT00438828
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
Study: NCT02143466
Drug: Part B - AZD9291 in combination with selumetinib
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent \[4 days on/3 days off\]) to further investigate the safety and tolerability of this combination.
Study: NCT02143466
Drug: Part C - AZD6094 monotherapy (Japan only)
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.
Study: NCT04868175
Drug: Timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
Study: NCT04868175
Drug: Travatan
Normalized name: Travatan
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
Study: NCT04868175
Drug: Hypromellose
Normalized name: Hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drop, lubricant
Study: NCT03914742
Drug: PARP Inhibitor BGB-290
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03914742
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04612673
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: immune checkpoint inhibitor, 200mg, iv, d1,Q3W
Study: NCT00771823
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Placebo twice daily for the first 14 days of the study.~* Maraviroc 300 mg twice daily for the last 14 days of the study.
Study: NCT00036270
Drug: exemestane (Aromasin)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exemestane, orally, 25 mg, for 5 years
Study: NCT00036270
Drug: tamoxifen + exemestane
Normalized name: Exemestane
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
Study: NCT03747458
Drug: OPN-375
Normalized name: anti-Tlr2 monoclonal antibody OPN-305
DrugBank: Tomaralimab (DB15415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPN-375, BID
Study: NCT03248063
Drug: Cloxacillin
Normalized name: Cloxacillin
DrugBank: Cloxacillin (DB01147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion. This treatment will be administered for at least 7 days by intravenous route.~Dosing regimen will be adapted in patients with chronic renal failure (glomerular filtration rate below 30ml/min/1.73m²) and in patient with impaired hepatic function associated with renal impairment whatever the level of the estimation of the glomerular filtration rate, according to SPC.
Study: NCT03248063
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC. As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
Study: NCT00779792
Drug: clobetasol
Normalized name: Clobetasol
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
Study: NCT00042146
Drug: zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00779792
Drug: triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg ointment twice daily for 10 consecutive days
Study: NCT00178373
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00178373
Drug: sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03920007
Drug: ATSN-101
Normalized name: ATSN-101
DrugBank: ATSN-101 (DB18327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
Study: NCT03920007
Drug: ATSN-101 Diluent Solution
Normalized name: ATSN-101
DrugBank: ATSN-101 (DB18327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
Study: NCT03920007
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT03920007
Drug: Triamcinalone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
Study: NCT00779792
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
Study: NCT03920007
Drug: Trimethoprim/polymyxin B
Normalized name: Polymyxin B Sulfate/Trimethoprim Sulfate 10000 U/1 ML-1 MG/1 ML Ophthalmic Solution [TRIMETHOPRIM/POLYMYXIN B SULF]
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution Route of administration: Topical
Study: NCT03724149
Drug: Zepatier
Normalized name: Zepatier
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Study: NCT00779792
Drug: glycerol
Normalized name: Glycerol
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
Study: NCT00779792
Drug: vehicle ointment (paraffin oil/soft white paraffin)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg vehicle ointment twice daily for 10 consecutive days
Study: NCT03724149
Drug: Epclusa
Normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Study: NCT00163449
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy and Safety of Ciclesonide
Study: NCT02051309
Drug: Guanfacine
Normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
Study: NCT01284439
Drug: hydroxypropylmethylcellulose
Normalized name: hydroxypropylmethylcellulose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
Study: NCT01284439
Drug: sodium hyaluronate
Normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QID to every 2 hous, 1-2 drops per each time, duration 1 month
Study: NCT01718938
Drug: velusetrag dose 1
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01718938
Drug: velusetrag dose 2
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01718938
Drug: velusetrag dose 3
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00056160
Drug: CC-5013
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
Study: NCT00056160
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
Study: NCT00411866
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole will be available as 200mg tablets.
Study: NCT02984111
Drug: erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00927602
Drug: fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily sc injection, 1,5 mg, max 14 days
Study: NCT04258163
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days
Study: NCT04258163
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg IH Days 0, 14, 28, then every 28 days
Study: NCT04258163
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg PO qd
Study: NCT04258163
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg PO qd
Study: NCT00152282
Drug: Asoprisnil/Premarin
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Study: NCT01621022
Drug: bupropion + nicotine gum
Normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
Study: NCT01621022
Drug: Placebo bupropion-Placebo gum
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
Study: NCT02515422
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous infiltration of ketamine
Study: NCT02515422
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous infiltration of bupivacaine
Study: NCT02515422
Drug: Placebo (0.9% saline solution)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01075581
Drug: Epinephrin (Intranasal injection)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
Study: NCT01075581
Drug: Epinephrin (Topical administration)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
Study: NCT00583258
Drug: Placebo Alfuzosin
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg PO once a day
Study: NCT03654196
Drug: Umkamin(Active Comparator)
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]
Study: NCT01195298
Drug: Capecitabine and Bevacizumab
Normalized name: Capecitabine
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drugs will be administered in 3-week cycles as follows:~* Bevacizumab 15mg/kg via i.v. infusion on day 1~* Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14.
Study: NCT00444145
Drug: Prevacid
Normalized name: Prevacid
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg bid for 3 months
Study: NCT04814745
Drug: intrathecal infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine 150 mcg will be used by intrathecal administration
Study: NCT04814745
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bilateral transversus abdominis plane block by using ropivacaine 80 mg
Study: NCT00775177
Drug: Doxycycline monohydrate 100mg tablets
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
Study: NCT00592098
Drug: Strontium chloride hexahydrate
Normalized name: Strontium Chloride Hexahydrate
DrugBank: Strontium chloride (DB13987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
Study: NCT04047290
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 is a PD1/VEGF bispecific antibody.
Study: NCT03155048
Drug: oral estrogen replacement therapy
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral estradiol group for endometrial preparation
Study: NCT00002725
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01204554
Drug: Indocyanine green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
Study: NCT03830125
Drug: BBT-877, Single dose
DrugBank: BBT-877 (DB18668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of BBT-877, 5 dose levels, oral capsule
Study: NCT03830125
Drug: BBT-877, Multiple doses
DrugBank: BBT-877 (DB18668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule
Study: NCT02423902
Drug: Veledimex
Normalized name: Veledimex
DrugBank: Veledimex (DB12170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 oral doses of veledimex
Study: NCT03092453
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered 7-8 weeks after subject's last DC dose
Study: NCT00152282
Drug: Asoprisnil/Premarin
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Study: NCT00152282
Drug: Asoprisnil/Premarin
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Study: NCT02812849
Drug: Cu-64 DOTATATE
Normalized name: copper Cu-64 dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03204019
Drug: Tegafur and Temozolomide
Normalized name: tegafur
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
Study: NCT03204019
Drug: Tegafur and Temozolomide combined with Thalidomide
Normalized name: tegafur
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
Study: NCT00002554
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02429271
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02429271
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01255878
Drug: Gabapentine
Normalized name: Gabapentine
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg(1 capsule)three times per day for two months
Study: NCT01186588
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 300-mg dose of canagliflozin on Day 1
Study: NCT00073177
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03128411
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive bosutinib at a starting dose of 400 mg QD.
Study: NCT03928353
Drug: PB2452 Infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 minute - 24 hour infusion
Study: NCT00419770
Drug: deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg/kg enterally per day
Study: NCT00419770
Drug: Liposomal amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03928353
Drug: Placebo - Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 minute - 24 hour infusion
Study: NCT03928353
Drug: Ticagrelor Oral Tablet - Pre-Treatment
Normalized name: ticagrelor Oral Tablet
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
Study: NCT03928353
Drug: Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Normalized name: hydrocortisone
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo
Study: NCT03928353
Drug: Ticagrelor Oral Tablet - Pre-Treatment
Normalized name: ticagrelor Oral Tablet
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
Study: NCT03928353
Drug: PB2452 Infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 minute - 16 hour infusion
Study: NCT03928353
Drug: Placebo - Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo - Sodium Chloride
Study: NCT03501459
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01494506
Drug: MM-398
Normalized name: sodium phosphate, dibasic 398 MG
DrugBank: Sodium phosphate, dibasic (DB14502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W
Study: NCT04002297
Drug: zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as two 80 mg capsules by mouth twice a day
Study: NCT03456570
Drug: Dydrogesterone 10 mg
Normalized name: dydrogesterone 10 MG
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone 10 mg twice daily
Study: NCT04002297
Drug: bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
Study: NCT04002297
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6